NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · CLOV · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Clover Health Investments, Corp.’s quoted price sits in the upper half of its reported 52-week range, 18.07% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Clover Health Investments, Corp.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of -$0.01. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Clover Health Investments, Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Clover Health Investments, Corp. is a U.S.-based firm specializing in Medicare Advantage insurance. The company leverages its proprietary software platform, the Clover Assistant, to provide both Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) health plans for individuals eligible for Medicare. In addition to its insurance operations, Clover Health also engages in non-insurance-related business ventures. The company was established in 2014 and its main office is located in Franklin, Tennessee.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 6, 2025 | $0.05+171.43% vs estimate | $462.33M-0.99% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | -$0.04+42.86% vs estimate | $336.96M-3.01% vs estimate |
|---|
| Q3 2024 | Nov 6, 2024 | -$0.02-50.04% vs estimate | $330.99M-4.9% vs estimate |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 4 contributors · Median target $5.75.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$90.33+$0.38 (+0.42%)
CVS Health Corp.’s quoted price sits in the upper half of its reported 52-week range, 18.39% below the high.
$298.41+$3.41 (+1.16%)
Cigna Corporation’s quoted price sits in the upper half of its reported 52-week range, 5.65% below the high.
$417.56+$5.69 (+1.38%)
Humana Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.53% below the high.
$68.62+$1.57 (+2.34%)
Centene Corp.’s quoted price sits in the upper half of its reported 52-week range, 5.35% below the high.
$30.79+$0.31 (+1.02%)
Oscar Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.05% below the high.
$8.06-$0.12 (-1.47%)
Alignment Healthcare, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.91% below the high.
